Scarica l'app Stockscreener
10.97
0.36%
-0.04
Pre-mercato:
10.76
-0.21
-1.91%
Precedente Chiudi:
$11.01
Aprire:
$11.07
Volume 24 ore:
1.04M
Relative Volume:
1.79
Capitalizzazione di mercato:
$685.15M
Reddito:
-
Utile/perdita netta:
$-69.71M
Rapporto P/E:
-9.1915
EPS:
-1.1935
Flusso di cassa netto:
$-54.12M
1 W Prestazione:
-23.66%
1M Prestazione:
-17.95%
6M Prestazione:
+31.38%
1 anno Prestazione:
+183.46%
Intervallo 1D:
$10.80
$11.43
Intervallo di 1 settimana:
$10.00
$16.95
Portata 52W:
$3.33
$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Nome
Design Therapeutics Inc
Settore
Industria
Telefono
858-293-4900
Indirizzo
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
10.97 | 687.65M | 0 | -69.71M | -54.12M | -1.1935 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Iniziato | Jefferies | Buy |
| 2026-01-07 | Iniziato | Oppenheimer | Outperform |
| 2025-12-03 | Iniziato | Craig Hallum | Buy |
| 2025-12-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-05-04 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-06-10 | Iniziato | Wedbush | Outperform |
| 2022-05-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-19 | Iniziato | Goldman | Sell |
| 2021-04-20 | Iniziato | Goldman | Neutral |
| 2021-04-20 | Iniziato | Piper Sandler | Overweight |
| 2021-04-20 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Design Therapeutics Inc Borsa (DSGN) Ultime notizie
Design Therapeutics (DSGN) Holds Steady Near Support as Consolidation PersistsVerified Analyst Reports - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Quiet QuarterGuidance Accuracy Score - Newser
Design Therapeutics (DSGN) price target increased by 17.05% to 17.51 - MSN
Design Therapeutics (DSGN) Edges Higher as Support Holds Above $10.60Social Trading Insights - Newser
Design Therapeutics Inc. (DSGN) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Gene Therapy PipelineRevenue Inflection Point - Newser
Analysts Conflicted on These Healthcare Names: Design Therapeutics (DSGN), Pro Medicus Limited (OtherPMCUF) and Boston Scientific (BSX) - The Globe and Mail
BlossomHill Therapeutics Expands Board of Directors with the Appointments of Sheila Gujrathi, M.D., and John Schmid - The Manila Times
DT-216P2 Shows Dose-Dependent Frataxin Increases and Clinical Improvements After 4 Weeks of IV Dosing in Friedreich Ataxia - Neurology Live
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20 - Moomoo
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Design Therapeutics stock wobbles after rare genetic disease data - MSN
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich AtaxiaSlideshow (NASDAQ:DSGN) 2026-05-19 - Seeking Alpha
Nasdaq Down 200 Points; Brady Earnings Top Views - Sahm
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In May - Sahm
Design Therapeutics (DSGN) Stock Forum and Discussion - Moomoo
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data - Sahm
Design Therapeutics, Inc. Stock 12‑Month Price Target Raised to $20, Implies 39% Upside - TradingView
Design Therapeutics Down Over 25%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk - Moomoo
RBC Capital raises Design Therapeutics price target on trial data By Investing.com - Investing.com Australia
Design Therapeutics Announces Biomarker and Clinical Data from Ongoing Phase 1/2 RESTORE-FA Trial of DT-216P2 in Friedreich Ataxia Patients - Minichart
Design Therapeutics reports positive trial data for FA treatment - Investing.com UK
Design Therapeutics reports positive trial data for FA treatment By Investing.com - Investing.com Australia
RBC Capital raises Design Therapeutics price target on trial data - Investing.com UK
DESIGN THERAPEUTICS, INC. (DSGN) - MSN
DSGN: DT-216P2 demonstrated strong biomarker and clinical improvements, supporting registrational plans - TradingView
Design Therapeutics Shares Jump on Encouraging Friedreich Ataxia Trial Results (DSGN) - Yahoo Finance
DSGN: DT-216 delivers rapid, significant frataxin increases and clinical benefit in FA patients - TradingView
Design Therapeutics reports Phase 1/2 trial data for DT-216P2 in Friedreich ataxia - Investing.com Nigeria
Design Therapeutics reports positive Phase 1/2 DT-216P2 data - TipRanks
Design Therapeutics' DT-216P2 Shows Clinical Improvements in Friedreich Ataxia Trial; Shares Rise Pre-Bell - marketscreener.com
Design Therapeutics stock surges on positive trial data By Investing.com - Investing.com South Africa
Design Therapeutics stock surges on positive trial data - Investing.com
RESTORE-FA data push Design Therapeutics (DSGN) to plan registrational path - Stock Titan
Design Therapeutics announces four-week IV data from the RESTORE-FA trial of DT-216P2 demonstrating clinical improvements and comprehensive biomarker activity in Friedreich Ataxia - marketscreener.com
DSGN: DT-216P2 showed dose-dependent clinical and biomarker improvements in Friedreich ataxia - TradingView
Design Therapeutics Announces Four-Week IV Data From The RESTORE-FA Trial Of DT-216P2 Demonstrating Clinical Improvements And Comprehensive Biomarker Activity In Friedreich Ataxia - TradingView
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia - The Manila Times
Jim Cramer: Design Therapeutics is 'pure spec,' buy this health care stock - MSN
User - The Chronicle-Journal
Design Therapeutics to present Phase 1/2 trial data for Friedreich’s ataxia drug DT-216P2 on May 18 - Pluang
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026 - The Manila Times
Design Therapeutics to Announce Phase 1/2 RESTORE-FA Trial Data for DT-216P2 in Friedreich's Ataxia on May 18, 2026 - Quiver Quantitative
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 ... - Caledonian Record
Friedreich’s ataxia trial data to be unveiled in May 18 webcast - Stock Titan
Jim Cramer on Design Therapeutics: “Pure Spec, Pure Spec” - Insider Monkey
Design Therapeutics Inc Azioni (DSGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):